American researchers conducted a meta-analysis of implantable devices designed to facilitate the intrathecal administration of nusinersen, one of three innovative therapies commonly used for SMA:
- the authors searched various medical literature databases using the PRISMA methodology,
- eight studies involving a total of 74 patients with SMA were selected,
- the various devices were always used off-label and were very diverse, both in terms of the method of implantation and the anatomical region considered,
- adverse effects were common (up to 27%) and required repeat surgery in nine patients.
This study reveals a lack of consensus on the indications for these devices, which could hinder their widespread use.
